166 related articles for article (PubMed ID: 35396711)
1. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.
Andersen MD; Hamilton-Dutoit S; Modvig L; Vase M; Christiansen I; Christensen JH; Dahl-Sørensen RB; Stoltenberg D; Kamper P; d'Amore F
Br J Haematol; 2022 Jul; 198(1):50-61. PubMed ID: 35396711
[TBL] [Abstract][Full Text] [Related]
2. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials.
Bröckelmann PJ; Goergen H; Kohnhorst C; von Tresckow B; Moccia A; Markova J; Meissner J; Kerkhoff A; Ludwig WD; Fuchs M; Borchmann P; Engert A
J Clin Oncol; 2017 May; 35(13):1444-1450. PubMed ID: 28240973
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015.
Juntikka T; Malila N; Ylöstalo T; Merikivi M; Jyrkkiö S
Acta Oncol; 2020 May; 59(5):574-581. PubMed ID: 31910680
[No Abstract] [Full Text] [Related]
4. Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma.
Pinczés L; Miltényi Z; Illés Á
J Cancer Res Clin Oncol; 2018 May; 144(5):935-943. PubMed ID: 29468437
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
6. Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres.
Illés A; Simon Z; Tóth E; Rosta A; Miltényi Z; Molnár Z
Pathol Oncol Res; 2008 Dec; 14(4):411-21. PubMed ID: 18431694
[TBL] [Abstract][Full Text] [Related]
7. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.
Ali S; Olszewski AJ
Leuk Lymphoma; 2014 Jul; 55(7):1570-7. PubMed ID: 24067135
[TBL] [Abstract][Full Text] [Related]
8. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
9. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and staging of Hodgkin lymphoma].
Ghesquières H
Rev Prat; 2023 Jun; 73(6):617-620. PubMed ID: 37458549
[TBL] [Abstract][Full Text] [Related]
11. Population-based study of Hodgkin's lymphoma in Kuwait.
Alshemmari S; Sajnani KP; Refaat S; Albassami A
Gulf J Oncolog; 2011 Jan; (9):20-6. PubMed ID: 21177205
[TBL] [Abstract][Full Text] [Related]
12. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.
Saarinen S; Pukkala E; Vahteristo P; Mäkinen MJ; Franssila K; Aaltonen LA
J Clin Oncol; 2013 Mar; 31(7):938-43. PubMed ID: 23284040
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features and therapy outcome in childhood Hodgkin's lymphoma: a report from tertiary care center in Saudi Arabia.
Alkhayat N; Alshahrani M; Elyamany G; Sedick Q; Ibrahim W; Hamzi H; Binhassan A; Othman M; Alshieban S; Aljabry MS; Asiri S; Alzouman M; Alsuhaibani O; Alabbas F; Alsharif O; Elborai Y
J Egypt Natl Canc Inst; 2021 Aug; 33(1):21. PubMed ID: 34396456
[TBL] [Abstract][Full Text] [Related]
14. Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma.
Akhtar S; Rauf MS; Al-Kofide A; Elshenawy MA; Mushtaq AH; Maghfoor I
Hered Cancer Clin Pract; 2021 Feb; 19(1):17. PubMed ID: 33563316
[TBL] [Abstract][Full Text] [Related]
15. Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
Modvig L; Vase M; d'Amore F
Br J Haematol; 2017 Oct; 179(1):75-82. PubMed ID: 28653321
[TBL] [Abstract][Full Text] [Related]
16. Childhood use of antimicrobials and risk of Hodgkin lymphoma: a Danish register-based cohort study.
Hjalgrim H; Søegaard SH; Hjalgrim LL; Rostgaard K
Blood Adv; 2019 May; 3(9):1489-1492. PubMed ID: 31072834
[TBL] [Abstract][Full Text] [Related]
17. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975
[TBL] [Abstract][Full Text] [Related]
18. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.
Shankar A; Daw S
Br J Haematol; 2012 Nov; 159(3):288-98. PubMed ID: 22994199
[TBL] [Abstract][Full Text] [Related]
19. Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study.
Kalashnikov I; Tanskanen T; Pitkäniemi J; Malila N; Jyrkkiö S; Leppä S
Blood Cancer J; 2021 Dec; 11(12):203. PubMed ID: 34923571
[TBL] [Abstract][Full Text] [Related]
20. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
